Results 41 to 50 of about 181,580 (299)

Faricimab Treat-and-Extend for Diabetic Macular Edema

Ophthalmology
Purpose: To evaluate the 2-year efficacy, durability, and safety of dual angiopoietin-2 and vascular endothelial growth factor (VEGF) A pathway inhibition with intravitreal faricimab according to a personalized treat-andextend (T&E)-based regimen with up to every-16-week dosing in the YOSEMITE and RHINE (ClinicalTrials.govidentifiers, NCT03622580 and ...
WONG, T, YOSEMITE AND RHINE INVESTIGATORS, YOSEMITE and RHINE Investigators   +2 more
openaire   +2 more sources

Optimal approaches and criteria to treat-and-extend regimen implementation for Neovascular age-related macular degeneration: experts consensus in Taiwan

BMC Ophthalmology, 2022
The management of neovascular age-related macular degeneration (nAMD) has taken a major stride forward with the advent of anti-VEGF agents. The treat-and-extend (T&E) approach is a refined management strategy, tailoring to the individual patient’s ...
Cheng-Kuo Cheng, Shih-Jen Chen, Jiann-Torng Chen, Lee-Jen Chen, San-Ni Chen, Wen-Lu Chen, Sheng-Min Hsu, Chien-Hsiung Lai, Shwu-Jiuan Sheu, Pei-Chang Wu, Wei-Chi Wu, Wen-Chuan Wu, Chung-May Yang, Ling Yeung, Ta-Ching Chen, Chang-Hao Yang   +15 more
doaj   +1 more source

Pharmacoeconomic research of using aflibercept in patients with the wet age-related macular degeneration

Российский офтальмологический журнал, 2020
Purpose. To evaluate the economic and clinical results of the aflibercept and ranibizumab angiogenesis inhibitors in the treat-and-extend regimen in patients with the “wet” form of age-related macular degeneration (wAMD). Materials and methods.
S. V. Nedogoda, A. S. Salasyuk, E. V. Bobykin, I. N. Barykina, V. O. Smirnova, E. A. Popova   +5 more
doaj   +1 more source

Using Extended Cognitive Behavioral Treatment and Medication to Treat Dependent Smokers

American Journal of Public Health, 2011
Objectives. We evaluated smoking-cessation efficacy of an extended course of sustained-release bupropion (bupropion SR) and cognitive-behavioral treatment (CBT). Methods. Participants who smoked at least 10 cigarettes per day and who smoked within 30 minutes of arising (n = 406) completed a 12-week smoking-cessation treatment including group ...
Sharon M, Hall, Gary L, Humfleet, Ricardo F, Muñoz, Victor I, Reus, Judith J, Prochaska, Julie A, Robbins   +5 more
openaire   +3 more sources

A simulation tool for better management of retinal services

BMC Health Services Research, 2018
Background Advances in the management of retinal diseases have been fast-paced as new treatments become available, resulting in increasing numbers of patients receiving treatment in hospital retinal services. These patients require frequent and long-term
Eren Demir, David Southern, Aimee Verner, Winfried Amoaku   +3 more
doaj   +1 more source

Long-term outcomes of intravitreal anti-VEGF therapies in patients affected by neovascular age-related macular degeneration: a real-life study

BMC Ophthalmology, 2021
Purpose To describe real-life data from wet age-related macular degeneration (AMD) patients treated with anti-vascular endothelial growth factors (VEGFs) and to compare our results with previous studies and clinical trials.
Paolo Corazza, Francesco Maria D’Alterio, Jamil Kabbani, Mostafa Mohamed Ragheb Alam, Stefano Mercuri, Harry Otway Orlans, Saad Younis   +6 more
doaj   +1 more source

Extended-Release Glipizide Overdose Presenting with Delayed Hypoglycemia and Treated with Subcutaneous Octreotide [PDF]

Journal of Pediatric Endocrinology and Metabolism, 2009
The onset of symptomatic hypoglycemia in children with ingestions of second-generation sulfonylureas has never been documented to be later than 21 hours post-ingestion. We report a case with the longest known interval, 45 hours, between ingestion of a sulfonylurea and the onset of hypoglycemia requiring medical intervention. The hypoglycemia was severe
Paul I, Pelavin, Erika, Abramson, Steven, Pon, Maria G, Vogiatzi   +3 more
openaire   +2 more sources

Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study [PDF]

British Journal of Ophthalmology, 2015
To demonstrate non-inferiority of ranibizumab treat-and-extend (T&E) with/without laser to ranibizumab pro re nata (PRN) for best-corrected visual acuity (BCVA) in patients with diabetic macular oedema (DMO).A 24-month single-masked study with patients randomised 1:1:1 to T&E+laser (n=121), T&E (n=128) or PRN (control; n=123).
Prunte C., Fajnkuchen F., Mahmood S., Ricci F., Hatz K., Studnicka J., Bezlyak V., Parikh S., Stubbings W. J., Wenzel A., Figueira J.   +10 more
openaire   +3 more sources

TREAT-AND-EXTEND BEVACIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

Retina, 2014
To evaluate the factors affecting visual and anatomical outcomes and the number of intravitreal bevacizumab injections required in the treatment of neovascular age-related macular degeneration using a treat-and-extend regimen.Retrospective consecutive case series.
Rush, R, Simunovic, M, Vandiver, L, Aragon, A, Ysasaga, J   +4 more
openaire   +2 more sources

Personalizing the Pediatric Hematology/Oncology Fellowship: Adapting Training for the Next Generation

Pediatric Blood &Cancer, EarlyView.
ABSTRACT The pediatric hematology‐oncology fellowship training curriculum has not substantially changed since its inception. The first year of training is clinically focused, and the second and third years are devoted to scholarship. However, this current structure leaves many fellows less competitive in the current job market, resulting in ...
Scott C. Borinstein, Melissa J. Rose, Scott Moerdler, Richard Ho   +3 more
wiley   +1 more source